Skip to main content
Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
0.698
+0.053 (8.20%)
At close: Jan 3, 2025, 4:00 PM
0.700
+0.002 (0.30%)
After-hours: Jan 3, 2025, 5:14 PM EST

Lyell Immunopharma Revenue

Lyell Immunopharma had revenue of $34.00K in the quarter ending September 30, 2024, with 36.00% growth. This brings the company's revenue in the last twelve months to $63.00K, down -99.87% year-over-year. In the year 2023, Lyell Immunopharma had annual revenue of $130.00K, down -99.85%.

Revenue (ttm)
$63.00K
Revenue Growth
-99.87%
P/S Ratio
n/a
Revenue / Employee
$281
Employees
224
Market Cap
194.87M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2023130.00K-84.55M-99.85%
Dec 31, 202284.68M74.03M695.15%
Dec 31, 202110.65M2.89M37.31%
Dec 31, 20207.76M7.10M1,080.52%
Dec 31, 2019657.00K--
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 393.90B
Johnson & Johnson 87.70B
Merck & Co. 63.17B
AbbVie 55.53B
AstraZeneca 51.21B
Novartis AG 49.94B
Thermo Fisher Scientific 42.37B
Abbott Laboratories 41.22B
Revenue Rankings

LYEL News

More News